Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Choose from a selection of modern and traditional designs in single or twin packs to support type 1 diabetes research this Christmas. Shop online and get fast delivery.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
This World Diabetes Day, we’re inviting you to celebrate by wearing your most joyful, whimsical and downright wonderful outfits.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
JDRF has now rebranded to Breakthrough T1D. Our name has changed, our mission has not.
Home > News & events > News > Top 10 research priorities for adults living with type 1 diabetes
A new research paper titled “The Top Ten Priorities in Adults Living with Type 1 Diabetes in Ireland and the United Kingdom – A James Lind Alliance Priority Setting Partnership” has been published in Diabetic Medicine. It highlights the most pressing concerns and priorities of adults living with type 1 diabetes.
The study was conducted through a collaborative effort by people living with type 1 diabetes, their families, diabetes charities like us and clinicians across Ireland and the United Kingdom, using the James Lind Alliance (JLA) Priority Setting Partnership (PSP) approach. JLA PSPs bring patients, carers, clinicians and charities together to establish the real concerns and priorities of people directly impacted by a condition, ensuring that future research focuses on what is most important to them. This work represents a significant step forward in person-centred care and research, ensuring that the voices of people living with type 1 diabetes are heard and acted upon.
The 10 research priorities reflect the varied issues that are most important to people affected by type 1 diabetes. Their purpose is to help funding organisations, like ourselves, and researchers ensure they address the key concerns of people living with type 1 in their future work.
Dr Christine Newman, the lead author of the study, said:
“This study is a powerful example of how Public and Patient Involvement can shape the future of healthcare. This work highlights the real-world challenges and unmet needs of adults living with type 1 diabetes. By focusing on these top 10 priorities, we can ensure that future research and healthcare services are aligned with what truly matters to those affected by the condition.”
The priorities cover a range of topics including type 1 technology, diabetes distress, ageing, insulin resistance and access to new treatments.
You can find the full list of research questions in the paper published in Diabetic Medicine.
The Priority Setting Partnership designed and shared a survey which asked people affected by type 1 to list three questions about type 1 diabetes. Over a thousand people responded to the first survey, most of whom are adults living with type 1 diabetes, as well as some healthcare professionals and family members of people living with type 1.
The Priority Setting Partnership members then sent out a second survey asking participants to rank 65 research questions from the first survey responses in order of importance. The top 19 questions were taken to a final workshop, held over two days, where the top 10 priorities were finalised and ranked.
Three members of JDRF UK were part of the Priority Setting Partnership that facilitated the focus groups to discuss and help narrow down the key priorities for people living with type 1.
Rachel Connor, Director of Research Partnerships at JDRF UK and co-author of the new research paper, said:
“Research MUST reflect the needs of people who live with type 1 diabetes. Over a thousand people living with type 1 and their loved ones participated in this exercise and by doing so they provided a unique picture of the challenges they face and their hopes for managing the condition in the future. These 10 priorities can guide researchers and research funders alike in focusing on the areas of research that will deliver the impact that people with type 1 diabetes want to see in their lives.”
The current priorities are an updated version of those set through a similar study in 2011, but which didn’t include people in Ireland. Over the past decade, we have used these priorities, which focused on diabetes technology, mental health, diabetes complications, and hypoglycaemia, to guide our research and advocacy work. The top three research questions from 2011 have now been addressed, with continuous glucose monitoring (CGM) and HCL technology available on the NHS for most people living with type 1 in England, Scotland and Wales.
Our continuous funding to develop type 1 technology and secure access on the NHS has only been possible thanks to our generous supporters. We will now use these 10 new research priorities to ensure the research we fund continues to meet the changing needs of people living with type 1 diabetes.
Professor David Baker, a Breakthrough T1D-funded researcher at the University of Washington, has been awarded a Nobel Prize in Chemistry.
When given to mice and pigs with type 1 diabetes, a new type of oral insulin developed with JDRF funding detects rising blood glucose and quickly lowers it to a safe level without causing hypos.
New research finds that ustekinumab, a drug commonly used to treat psoriasis, may help children and adolescents with type 1 diabetes keep making insulin for longer.
New international guidance detailing how to monitor and support people with early-stage type 1 diabetes (T1D) has the potential to reduce the trauma associated with being diagnosed with T1D, enable people to access the latest treatments to delay the need for insulin therapy, and reduce long-term health complications.
Donate now to help fund our ongoing research to improve life for people with type 1 diabetes until we find cures.